<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02029924</url>
  </required_header>
  <id_info>
    <org_study_id>BC3-CT006</org_study_id>
    <nct_id>NCT02029924</nct_id>
  </id_info>
  <brief_title>A Double-blinded, Randomised, Two -Period Crossover Euglycemic Clamp Trial Investigating the Pharmacokinetics, Glucodynamics and Safety of BioChaperone Insulin Lispro and Insulin Lispro (Humalog®) in Subjects With Type 1 Diabetes</brief_title>
  <official_title>A Double-blinded, Randomised, Two -Period Crossover Euglycemic Clamp Trial Investigating the Pharmacokinetics, Glucodynamics and Safety of BioChaperone Insulin Lispro and Insulin Lispro (Humalog®) in Subjects With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adocia</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Adocia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The addition of Biochaperone to insulin lispro may accelerate the onset and shorten the
      duration of action of insulin lispro due to a facilitation of the absorption of the insulin
      after subcutaneous injection.

      The aim of the trial is to assess the efficacy and safety of BioChaperone insulin lispro in
      subjects with Type 1 diabetes under a dose of 0.2 U/Kg.

      This trial is a single-center, randomised, double-blinded, two-treatment, two-period
      cross-over, 6-hour euglycaemic glucose clamp trial in subjects with Type 1 diabetes mellitus.
      Each subject will be randomly allocated to a single dose of BioChaperone insulin lispro 0.2
      U/Kg and a single dose of Humalog® 0.2 U/Kg on 2 separate dosing visits.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve (AUC)</measure>
    <time_frame>30 minutes</time_frame>
    <description>Area under the curve of the insulin lispro concentration - time curve from 0 to 30 minutes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Early t0.5max(Lisp)</measure>
    <time_frame>up to 6 hours post administration of study drug</time_frame>
    <description>Time to first observed half maximum observed insulin lispro concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucodynamics: Area under the glucose infusion rate - time curve from t=0 to 6 hours</measure>
    <time_frame>6 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucodynamics: Early t0.5(GIRmax)</measure>
    <time_frame>6 hours</time_frame>
    <description>Time to first observed half maximum glucose infusion rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucodynamic: GIRmax (Maximum glucose infusion rate)</measure>
    <time_frame>6 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area under the insulin lispro serum concentration. Time curve from t=0 to 6 hours</measure>
    <time_frame>6 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: tmax(Lisp) - Time from t=0 hours to maximum observed insulin lispro concentration</measure>
    <time_frame>6 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability: adverse events, local tolerability, vital signs variation, ECG, laboratory safety parameters</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Diabetes Mellitus Type 1</condition>
  <arm_group>
    <arm_group_label>BioChaperone insulin lispro</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BioChaperone insulin lispro</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Humalog®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Humalog®</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BioChaperone insulin lispro</intervention_name>
    <description>Single dose of 0.2 U/Kg body weight injected subcutaneously (under the skin)</description>
    <arm_group_label>BioChaperone insulin lispro</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Humalog®</intervention_name>
    <description>Single dose of 0.2 /Kg body weight injected subcutaneously (under the skin)</description>
    <arm_group_label>Humalog®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 1 diabetes mellitus for at least 12 months.

          -  Treated with multiple daily insulin injections or insulin pump for at least 12 months.

          -  Body Mass Index (BMI): 18.0-28.0 Kg/m².

        Exclusion Criteria:

          -  Type 2 diabetes mellitus.

          -  Receipt of any investigational product within 3 months prior to first dosing.

          -  Clinically significant abnormalities as judged by the investigator.

          -  Any systemic treatment with drugs known to interfere with glucose metabolism.

          -  History of alcoholism, or drug/chemical abuse as per Investigator's judgement.

          -  Use of tobacco or nicotine-contained product within 5 years prior to screening.

          -  Blood or plasma donation in the past month or more than 500 mL within 3 months prior
             to screening.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Neuss</city>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2013</study_first_submitted>
  <study_first_submitted_qc>January 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2014</study_first_posted>
  <last_update_submitted>May 31, 2017</last_update_submitted>
  <last_update_submitted_qc>May 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Lispro</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

